Updated safety, efficacy and PK results from an open-label, multicenter, Phase I/II study of avapritinib in Chinese patients with unresectable or metastatic gastrointestinal stromal tumors (GIST)

Efficacy and Safety of Pralsetinib, a Selective RET Inhibitor, in Chinese Patients with Advanced RET-mutant Medullary Thyroid Cancer

Efficacy and Safety of Pralsetinib, a Selective RET Inhibitor, in Chinese Patients with Advanced RET-mutant Medullary Thyroid Cancer (MTC)

GEMSTONE-304: A Phase III Study of Fluorouracil and Cisplatin (FP) with CS1001 (Sugemalimab), an Anti-PD-L1 Antibody, or Placebo in Unresectable Locally Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma (ESCC)

GEMSTONE-301: a phase III clinical trial of CS1001 as consolidation therapy in patients with locally advanced/unresectable (stage III) non-small cell lung cancer (NSCLC) who did not have disease progression after prior concurrent/sequential chemoradiotherapy

Efficacy and Safety of Pralsetinib in Chinese Patients with Advanced RET Fusion+ Non-Small Cell Lung Cancer

Abstract 2954 Efficacy and Safety of Pralsetinib in Chinese Patients with Advanced RET Fusion+ Non-Small Cell Lung Cancer after Platinum-Based Chemotherapy

Abstract 2240 GEMSTONE-302: a Phase 3 Study of Platinum-Based Chemotherapy (chemo) with Placebo or CS1001, an Anti- PD-L1 Antibody, for First-Line (1L) Advanced Non-Small Cell Lung Cancer (NSCLC)